188 related articles for article (PubMed ID: 19035475)
1. Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Kwan Tat S; Pelletier JP; Amiable N; Boileau C; Lajeunesse D; Duval N; Martel-Pelletier J
Arthritis Rheum; 2008 Dec; 58(12):3820-30. PubMed ID: 19035475
[TBL] [Abstract][Full Text] [Related]
2. Treatment with ephrin B2 positively impacts the abnormal metabolism of human osteoarthritic chondrocytes.
Kwan Tat S; Pelletier JP; Amiable N; Boileau C; Lavigne M; Martel-Pelletier J
Arthritis Res Ther; 2009; 11(4):R119. PubMed ID: 19664212
[TBL] [Abstract][Full Text] [Related]
3. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
[TBL] [Abstract][Full Text] [Related]
4. Ephrin B2/EphB4 mediates the actions of IGF-I signaling in regulating endochondral bone formation.
Wang Y; Menendez A; Fong C; ElAlieh HZ; Chang W; Bikle DD
J Bone Miner Res; 2014 Aug; 29(8):1900-13. PubMed ID: 24677183
[TBL] [Abstract][Full Text] [Related]
5. The protective role of Ephrin-B2/EphB4 signaling in osteogenic differentiation under inflammatory environment.
Qu F; Song Y; Wu Y; Huang Y; Zhong Q; Zhang Y; Fan Z; Xu C
Exp Cell Res; 2021 Mar; 400(2):112505. PubMed ID: 33516666
[TBL] [Abstract][Full Text] [Related]
6. Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts.
Amiable N; Tat SK; Lajeunesse D; Duval N; Pelletier JP; Martel-Pelletier J; Boileau C
Bone; 2009 Jun; 44(6):1143-50. PubMed ID: 19264156
[TBL] [Abstract][Full Text] [Related]
7. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Piffko A; Broggini T; Harms C; Adams RH; Vajkoczy P; Czabanka M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360793
[TBL] [Abstract][Full Text] [Related]
9. ED-71 Improves Bone Mass in Ovariectomized Rats by Inhibiting Osteoclastogenesis Through EphrinB2-EphB4-RANKL/OPG Axis.
Wang K; Kou Y; Rong X; Wei L; Li J; Liu H; Li M; Song H
Drug Des Devel Ther; 2024; 18():1515-1528. PubMed ID: 38716369
[TBL] [Abstract][Full Text] [Related]
10. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Noren NK; Lu M; Freeman AL; Koolpe M; Pasquale EB
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5583-8. PubMed ID: 15067119
[TBL] [Abstract][Full Text] [Related]
11. Sinusoidal ephrin receptor EPHB4 controls hematopoietic progenitor cell mobilization from bone marrow.
Kwak H; Salvucci O; Weigert R; Martinez-Torrecuadrada JL; Henkemeyer M; Poulos MG; Butler JM; Tosato G
J Clin Invest; 2016 Dec; 126(12):4554-4568. PubMed ID: 27820703
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Rutkowski R; Mertens-Walker I; Lisle JE; Herington AC; Stephenson SA
Int J Cancer; 2012 Sep; 131(5):E614-24. PubMed ID: 22161689
[TBL] [Abstract][Full Text] [Related]
13. Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Bai J; Wang YJ; Liu L; Zhao YL
J Int Med Res; 2014 Apr; 42(2):405-15. PubMed ID: 24517927
[TBL] [Abstract][Full Text] [Related]
14. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Noren NK; Yang NY; Silldorff M; Mutyala R; Pasquale EB
Biochem J; 2009 Aug; 422(3):433-42. PubMed ID: 19552627
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Duggineni S; Mitra S; Noberini R; Han X; Lin N; Xu Y; Tian W; An J; Pasquale EB; Huang Z
Biochem Pharmacol; 2013 Feb; 85(4):507-13. PubMed ID: 23253822
[TBL] [Abstract][Full Text] [Related]
16. Preliminary identification of potential PDZ-domain proteins downstream of ephrin B2 during osteoclast differentiation of RAW264.7 cells.
Mao Y; Huang X; Zhao J; Gu Z
Int J Mol Med; 2011 May; 27(5):669-77. PubMed ID: 21373749
[TBL] [Abstract][Full Text] [Related]
17. EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells.
Nguyen TM; Arthur A; Hayball JD; Gronthos S
Stem Cells Dev; 2013 Oct; 22(20):2751-64. PubMed ID: 23711177
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expression of interleukin-6, matrix metalloproteinase-13, and receptor activator of NF-kappaB ligand in cells derived from osteoarthritic subchondral bone.
Sakao K; Takahashi KA; Mazda O; Arai Y; Tonomura H; Inoue A; Saito M; Fujioka M; Takamiya H; Imanishi J; Kubo T
J Orthop Sci; 2008 May; 13(3):202-10. PubMed ID: 18528653
[TBL] [Abstract][Full Text] [Related]
19. Boning up on ephrin signaling.
Mundy GR; Elefteriou F
Cell; 2006 Aug; 126(3):441-3. PubMed ID: 16901775
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.
Bhatia S; Oweida A; Lennon S; Darragh LB; Milner D; Phan AV; Mueller AC; Van Court B; Raben D; Serkova NJ; Wang XJ; Jimeno A; Clambey ET; Pasquale EB; Karam SD
Cancer Res; 2019 May; 79(10):2722-2735. PubMed ID: 30894369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
